Tower Bridge Advisors lowered its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 1.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 94,447 shares of the medical instruments supplier’s stock after selling 1,530 shares during the period. Becton Dickinson and makes up about 2.5% of Tower Bridge Advisors’ holdings, making the stock its 4th biggest position. Tower Bridge Advisors’ holdings in Becton Dickinson and were worth $22,626,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Becton Dickinson and in the second quarter worth approximately $163,000. Tredje AP fonden lifted its holdings in shares of Becton Dickinson and by 6.7% in the second quarter. Tredje AP fonden now owns 34,659 shares of the medical instruments supplier’s stock valued at $8,303,000 after purchasing an additional 2,163 shares in the last quarter. Olstein Capital Management L.P. lifted its holdings in shares of Becton Dickinson and by 12.1% in the second quarter. Olstein Capital Management L.P. now owns 37,000 shares of the medical instruments supplier’s stock valued at $8,864,000 after purchasing an additional 4,000 shares in the last quarter. Staley Capital Advisers Inc. lifted its holdings in shares of Becton Dickinson and by 22.1% in the second quarter. Staley Capital Advisers Inc. now owns 2,625 shares of the medical instruments supplier’s stock valued at $629,000 after purchasing an additional 475 shares in the last quarter. Finally, Ausdal Financial Partners Inc. bought a new stake in Becton Dickinson and during the second quarter worth $278,000. 84.77% of the stock is owned by institutional investors and hedge funds.

Becton Dickinson and stock traded up $0.82 during mid-day trading on Tuesday, reaching $253.63. 5,456 shares of the company’s stock were exchanged, compared to its average volume of 947,837. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95. Becton Dickinson and Co has a one year low of $191.53 and a one year high of $254.35. The firm has a market capitalization of $67.73 billion, a P/E ratio of 26.82, a price-to-earnings-growth ratio of 1.72 and a beta of 1.13.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.86 by $0.05. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The business had revenue of $4.28 billion during the quarter, compared to the consensus estimate of $4.25 billion. During the same period last year, the business posted $2.46 earnings per share. The business’s revenue for the quarter was up 41.0% on a year-over-year basis. analysts predict that Becton Dickinson and Co will post 11.01 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 28th. Shareholders of record on Friday, September 7th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.18%. The ex-dividend date is Thursday, September 6th. Becton Dickinson and’s dividend payout ratio is currently 31.65%.

BDX has been the topic of a number of recent analyst reports. ValuEngine lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Tuesday, May 29th. JPMorgan Chase & Co. upgraded Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price target on the stock in a report on Thursday, June 21st. KeyCorp reiterated a “buy” rating and set a $264.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Royal Bank of Canada reiterated a “hold” rating and set a $248.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Finally, Citigroup lifted their price target on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Becton Dickinson and currently has an average rating of “Buy” and a consensus target price of $247.71.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Read More: Marijuana Stocks Future Looks Bright

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.